For example, many studies investigating associations with therapeutic efficacy of therapeutic antibodies against cancer have found an association with the FCGR3A-158V variant (rs396991) (13–15, 59), which we now show to be in moderate LD with the classic FCGR2C-ORF (r2 = 0.24). Here, FCGR2C is linked to cancer.